Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — Investor Presentation (October 2015)
25 slides from Inspiremd's investor presentation, Oct 15, 2015
Slide 1: InspireMD October 2015
NYSE MKT: NSPR October 2015
Slide 2: Forward Looking Statements
Forward Looking Statements 2 This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-look
Slide 3: Emerging medical device company for interventional cardiology
3 An emerging medical device company developing and commercializing advanced technology for interventional cardiology and other vascular procedures InspireMD NYSE MKT: NSPR Stock Price (10/14/15): $1.70 52 Week Range: $1.22 -$19.8 Average Volume: 74K Shares Outstanding (10/1/15): 7.8 M Market Capita
Slide 4: Investment Highlights
Investment Highlights 4 • 2015 return to revenue growth driven by the full launch of carotid platform through strategic distribution partnership with Penumbra, Inc. • Operating and financial realignment inline with development and growth initiatives. • Advancing into highly valued Neuroand Periphera
Slide 5: InspireMD
inspireMD roke Recov Study Find
Slide 6: Leadership: Significant Track Records of Success
6 Leadership: Significant Track Records of Success EXECUTIVETEAM BOARD OF DIRECTORS Alan Milinazzo, President, CEO & Director • Medtronic • Boston Scientific Craig Shore,CFO • Pfizer • General Electric Dr. James Barry, COO • Boston Scientific • Howmedica Division of Pfizer Eli Bar, CTO • Nicast Gwen
Slide 7: Technology: MicroNet
Technology: MicroNet™ 7 Proprietary MicroNetMesh for Embolic Prevention and Flow Diversion MicroNetPlatform Ultra thin PET enhances clinical benefit of scaffold devices • Provides revascularization benefit • MicroNet acts as safety net by offering greater surface area coverage to prevent large debri
Slide 8: Large Addressable Markets Expanding the MicroNet Platform
Large Addressable Markets 8 Expanding the MicroNet™ Platform MGuard™ x$1.7B Market xCE Mark Cleared xCoronary AMI, SVG CGuard™ x$500M Market xCE Mark Cleared xCarotid NVGuard x$125M Flow Diversion Market x$550M Aneurysm Market x2016E CE Mark Planned Submission for Flow Diverter xNeurovascular PVGuar
Slide 9: Carotid Market Opportunity
Carotid Market Opportunity 9 An Enhanced Minimally Invasive Solution • Standard of care: Open surgery: Carotid EndArterectomy(CEA) • Current stents have not improved on CEA stroke rates (CREST) • Mesh covered stent category has the potential to convert CEA to CAS • CARENET 30-day and 6-mo data show
Slide 10: Carotid Solution Emerging Market Opportunity
Carotid Solution 10 Emerging Market Opportunity CGuard™ Embolic Prevention System Combines stent and embolic protection in a single device • CE marked • Self-expanding nitinolstent • Global market valued at $500M* • Strong CARENET FIM data released 9/14 and 1/15 • Impressive all-comer data from PARA
Slide 11: Positive CGuard Clinical Experience: CARENET
Positive CGuard™ Clinical Experience 11 * FIM , First in Man CARENET (CARotidEmbolic protection using microNET) FIM* Clinical Trial • 30 Patient Safety and Efficacy clinical trial • Prospective, multi-center, multispecialty, non-randomized single arm study • DWMRI follow ups at 48hrs and 30 days for
Slide 12: Positive CGuard Clinical Experience: PARADIGM
Positive CGuard™ Clinical Experience 12 * FIM , First in Man PARADIGM (Prospective evaluation of All-comer perRcutaneous cArotiD revascularization In symptomatic and increased-risk asymptomatic carotid artery stenosis using CGuard TM Mesh-covered embolic prevention system) PhysicianInitiatedAll-Come
Slide 13: Strategic Distribution Partnership
Strategic Distribution Partnership 13 • Founded in 2005 as a Neurovascular company with a clinically-driven product development strategy. Very successful IPO in September. • Reputation as the innovation leader in the neurovascular field • Extending success beyond stroke into the periphery and neuros
Slide 14: Commercial Profile: Revenue Growth Driven by CGuard RX
- 200 400 600 800 1,000 1,200 1,400 1,600 1,800 Q1 Q2 Q3 Q4 2012 2013 2014 2015 Commercial Profile 14 Revenue Growth Driven by CGuard™ RX • Late September 2015: Full Total Systems Solution Launch • Key European Territories Targeted • Opportunity to Increase Number of Target Territories Note: Revenue
Slide 15: Robust Pipeline
Robust Pipeline 15 Commercial • CE Mark Cleared • 12-month MASTER I, II MicroNet™ Platform Technology MGuard™ Coronary EPS NVGuard™ Neurovascular* RGuard™ Renal* CGuard™ RX Carotid PVGuard™ Peripheral* MGuard™ Drug Eluting* *Planning & Development Phase Commercial • CE Mark Cleared • CARENET Tri
Slide 16: Neurovascular Market Opportunity
Neurovascular Market Opportunity 16 Innovation Leads Growth • Current designs have sub-optimal trackabilityand in vessel flexibility: metal on metal devices • MicroNethas proven flow diversion effect with ultra low profile and improves device flexiblityto improve device deliverability Source: MRG Ne
Slide 17: NVGuard Neurovascular Differentiation
NVGuard™ Neurovascular 17 Differentiation Yields Increased Utility Our Significant Advantage Over Existing Flow Diverters • MicroNetaperture & size • Low metal to artery ratio • Can be placed in side branches and bifurcations, which is impossible with current technology Total Aneurysm Market Value:
Slide 18: Neurovascular Market
Neurovascular Market 18 • Medtronic acquires Medina Medical for $150 million • Stryker Acquires Surpass Medical for $135 million • CovidienAcquires Chestnut Medical for $150 million * • Medtronic Acquires Lazarus Effect for $100 million *Based on milestones achieved as part of structured deal High S
Slide 19: Intellectual Property Portfolio
Intellectual Property Portfolio 19 Continue to strengthen and broaden patent protection globally. Progress over the last year imparts important rights on existing products and technologies and will enable future pipeline products Source: MRG PATENT RIGHTS Issued Allowed Pending US 4 0 9 Rest of Worl
Slide 20: Target Milestones 2015E-2017E
2015E 2016E 2017E R&D/Clin/Reg Corporate Operational Commercial Target Milestones 20 Support & Execute on Growth Initiatives Strategic Partnership : Penumbra Strategic Partnership V Strategic Partnership IV DES Estimated CE Mark Achieve Targeted COGS NVGuardCE Mark Submission CGuard RX Launch NVGuar
Slide 21: Investment Highlights
Investment Highlights 21 • 2015 return to revenue growth driven by the full launch of carotid platform through strategic distribution partnership with Penumbra, Inc. • Operating and financial realignment inline with development and growth initiatives. • Advancing into highly valued Neuroand Peripher
Slide 22: Alan Milinazzo, CEO (888) 776-6804 alanm@inspiremd.com Craig Shore, CFO (888) 776-6804 craigs@inspiremd.com
Alan Milinazzo, CEO (888) 776-6804 alanm@inspiremd.com Craig Shore, CFO (888) 776-6804 craigs@inspiremd.com
Slide 23: Coronary MGuard EPS
Coronary MGuard™ EPS 23 Improving AMI Patient Outcomes • Current stents not specifically designed for AMI • Distal embolization occurs in up to 73% of cases* • Majority of AMI market is outside of the U.S. (~60%) • MGuardclinical experience including two randomized trials MASTER I and MASTER II with
Slide 24: MASTER I & II Pooled: All Cause Mortality
24 MASTER I & II Pooled: All Cause Mortality at 30 days (743 patients) 0 5 10 15 20 25 30 Time in Days BMS/DES (n=371) MGuard (n=372) 5 4 3 2 1 0 D e a t h ( % ) HR: 0.14 [95% CI: 0.02, 1.15] P=0.03 1.9% 0.3%
Slide 25: PVGuard Peripheral
PVGuard™ Peripheral 25 The Embolic Prevention System A new stent category as the preferred solution for peripheral intervention • Current stents not specifically designed for embolic protection • Mesh covered stent category emerging as immediate opportunity • Strong global growth profile with increa